Zacks Investment Research cut shares of Jounce Therapeutics (NASDAQ:JNCE) from a buy rating to a hold rating in a report issued on Wednesday morning.
According to Zacks, “Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company’s lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States. “
JNCE has been the topic of several other research reports. ValuEngine upgraded Jounce Therapeutics from a sell rating to a hold rating in a report on Thursday, August 2nd. JPMorgan Chase & Co. reduced their price target on Jounce Therapeutics from $12.00 to $10.00 and set a hold rating on the stock in a report on Friday, August 10th. Raymond James started coverage on Jounce Therapeutics in a report on Thursday, June 28th. They set an outperform rating and a $13.00 price target on the stock. HC Wainwright set a $13.00 price target on Jounce Therapeutics and gave the stock a buy rating in a report on Monday, August 13th. Finally, Cowen reiterated a hold rating on shares of Jounce Therapeutics in a report on Thursday, August 9th. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of $12.54.
Jounce Therapeutics (NASDAQ:JNCE) last posted its quarterly earnings results on Friday, August 10th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.23. Jounce Therapeutics had a negative return on equity of 23.27% and a negative net margin of 50.54%. The business had revenue of $19.38 million for the quarter, compared to analyst estimates of $12.47 million. As a group, equities research analysts expect that Jounce Therapeutics will post -1.26 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently modified their holdings of JNCE. Millennium Management LLC raised its holdings in Jounce Therapeutics by 91.6% in the 2nd quarter. Millennium Management LLC now owns 679,177 shares of the company’s stock valued at $5,202,000 after buying an additional 324,681 shares during the period. BlackRock Inc. raised its holdings in Jounce Therapeutics by 22.2% in the 2nd quarter. BlackRock Inc. now owns 1,394,905 shares of the company’s stock valued at $10,684,000 after buying an additional 253,120 shares during the period. Dimensional Fund Advisors LP raised its holdings in Jounce Therapeutics by 186.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 314,831 shares of the company’s stock valued at $2,412,000 after buying an additional 204,762 shares during the period. Redmile Group LLC raised its holdings in Jounce Therapeutics by 20.6% in the 1st quarter. Redmile Group LLC now owns 1,182,393 shares of the company’s stock valued at $26,426,000 after buying an additional 202,000 shares during the period. Finally, Spark Investment Management LLC raised its holdings in Jounce Therapeutics by 257.1% in the 2nd quarter. Spark Investment Management LLC now owns 215,700 shares of the company’s stock valued at $1,652,000 after buying an additional 155,300 shares during the period. Hedge funds and other institutional investors own 84.11% of the company’s stock.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.